Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Summary

Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC

Timeline

Start

2016-02

Primary completion

2017-11

Completion

2017-11

Publications

• Weinberg BA, Hartley ML, Salem ME. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation. Oncology (Williston Park). 2017 Jul 15;31(7):573-80.

Drugs

Indications